Osteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
|
|
- Arlene Shields
- 5 years ago
- Views:
Transcription
1 Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi
2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.
3 Barriers To Change
4 Disclosure of Commercial Support This program has not received financial support, or in-kind support, from any Pharmaceutical Company. Potential for conflict(s) of interest: None to declare
5 Faculty/Presenter Disclosure Faculty: Richard Bebb Relationships with commercial interests: None to report
6 What is Boys and Men s Health?
7 THESORRYSTATISTICS 84% more likely to die from arterial diseases 39% more likely to die from diabetes 29% more likely to be diagnosed with cancer and 40% more likely to die as a result 70% more likely to die from heart disease
8 THESORRYSTATISTICS 97% of workplace deaths (2005: 1,064 of 1,097) 35% of suicide attempts are male, but 80% of successful suicides 80% of spinal cord injuries, substance abuse, violence and crime
9 Learning Objectives: Appreciate the prevalence of male osteoporosis To review the available treatments for osteoporosis in men
10 Definitions: Osteoporosis 1913 Webster An absorption of bone so that the bone tissue becomes unusually porous. It occurs especially in elderly men and postmenopausal women, and predisposes the elderly to fractures of the bones consensus conference A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue with a resultant increase in bone fragility and risk of fracture NIH (US) modifications A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of two main features; bone density and bone quality Consensus development conference. Am J Med 1993;94: NIH Consensus Development Panel. JAMA 2001;285:
11 Definitions: BMD Results Status 1, 2 Normal T-score +2.5 to 1.0, inclusive Osteopenia Between 1.0 and 2.5 Osteoporosis Severe osteoporosis fragility fracture 1. Kanis JA, et al. J Bone Miner Res 1994;9: WHO, Geneva 1994.
12 Questions: 1) 1 in 8 men over age 50 will suffer an osteoporotic fracture (T/F) 2) Mortality related to osteoporosis in men is less than women (T/F) 3) Women are 6 times more likely to be treated after an osteoporotic fracture than men (T/F)
13 Fracture incidence rate per 10,000 population in Leicester, UK, by age and gender. From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.
14 Osteoporosis in Men 1 in 8 men over age 50 will suffer an osteoporotic fracture (1 in 4 for women) 30% of hip fractures occur in men More data needed to clarify BMD vs fracture risk in men BMD may reflect larger bone size Fracture risk also depends on likelihood of falls, bone size, geometry, as well as other health factors Josse RG. J Sex Reprod Med 2001 Melton LJI. J Bone Miner Res 1998 Gilsanz V, et al. Radiology 1994
15 Osteoporosis is often not treated in men Gender differences in bisphosphonate prescription: 1 in 4 women affected, 1 in 5 treated (20.4%) 1 in 8 men affected, 1 in 30 treated (3.3%) Treatment rates following atraumatic fracture requiring hospitalization: 4.5% of men treated at discharge (vs. 27% women) 27% of men treated at 5-year follow-up (vs. 71% women) CIHI 2009; Kiebzak Arch Intern Med 2002; Pajnu BJUI 2008
16 Mortality of hip fractures 30 % Men Women 5 0 Overall <75 years >75 years Poór et al., Osteoporosis Int 1995;5:419-26
17 Osteoporosis in Men: Summary Lower risk of osteoporotic fractures, BUT Less likely to be treated than women More likely to die after a fracture
18 Causes of Osteoporosis in Men From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.
19 Causes of Osteoporosis in Men From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.
20 Risk ratio for hip fracture in men Risk Factor Risk Ratio for Hip Fracture (95% CI) Parental history of hip fracture 2.28 ( ) Corticosteroids (>3 months) 2.25 ( ) Low testosterone 1.88 ( ) Rheumatoid arthritis 1.73 ( ) Excessive alcohol use 1.70 ( ) Prior fracture (> 50 yrs of age) 1.62 ( ) Current smoking 1.60 ( ) Low BMI (20 vs. 25) 1.42 ( ) High BMI (30 vs. 25) 1.00 ( ) Kanis Osteoporosis Int 2005; Meier Arch Intern Med 2008.
21 When to order Densitometry in Men: 1) Age 50 or older with 1 major or 2 minor risk factors 2) Age 65 or older 3) Younger patients with low-trauma fractures 4) In the presence of diseases or medications that predispose to bone loss or fracture
22 Major risk factors Age 65 or older Vertebral compression fracture Fragility fracture after age 40 Family history of osteoporotic fracture (especially maternal hip fracture) Systemic glucocorticoid therapy of at least 3 months duration Malabsorption syndrome Primary hyperparathyroidism Propensity to fall Appearance of osteopenia on radiograph Hypogonadism
23 Minor risk factors Rheumatoid arthritis History of hyperthyroidism / hyperparathyroidism Long-term anticonvulsant therapy Weight loss greater than 10% of weight at age 25 Weight less than 57 kg Smoking Excess alcohol intake Excess caffeine consumption Low dietary calcium intake Long-term heparin therapy
24 BMD vs Age and Fracture Prediction Fracture Risk vs. BMD At Different Ages Hui et al. J Clin Invest 1988; 81:1804-9
25 CATEGORIZATION BASED ON 10-YEAR FRACTURE RISK Absolute fracture risk in 10 years: low: <10% moderate: 10-20% high: >20%
26 USING LOWEST T-SCORE TO FIND 10- YEAR FRACTURE RISK - WOMEN LOWEST T-Score WOMEN Low Risk Moderate Risk High Risk AGE (years)
27 LOWEST T-Score USING LOWEST T-SCORE TO FIND 10- YEAR FRACTURE RISK - MEN Low Risk MEN Moderate Risk High Risk AGE (years)
28 Comparison of FRAX vs Garvan Fracture Risk assessment Tools Risk factor FRAX Garvan Age Yes Yes Gender Yes Yes Height Yes No Weight Yes No Previous fracture Yes Since age 50 Parental hip fracture Yes No Current smoking Yes No Glucocorticoid use Yes No Rheumatoid arthritis Secondary osteoporosis Yes Yes No No EtOH> 3 units daily Yes No Femoral neck BMD Yes Yes Falls in last 12 months URL No RAX/ Yes alculator.com Bone Research (2014) 2, 14001
29 FRAX results Consider treatment if: 10-yr probability of hip fracture > 3% 10-yr probability of major osteoporosis-related fracture > 20%
30 Laboratory Tests to exclude secondary causes of osteoporosis: Complete blood count (CBC) Serum calcium Total alkaline phosphatase Serum creatinine Serum protein electrophoresis Total (& bioavailable) testosterone, (Prolactin, LH, FSH if testosterone low) TSH 1. Modified from Osteoporosis Society of Canada. Can Med Assoc J 1996;155:
31 Case 65 y.o. man with osteopenia 2 years postbariatric surgery Is he at greater risk for fracture due to bariatric surgery?
32 Fracture Risk Fracture Incidence post-bariatric Surgery Healthcare databases, Québec, Canada ( ) (N= 12,676) (N= 38,028) (N= 126,760) Time (years) Rousseau, BMJ, 2016
33 Fracture-free survival rate Fracture Incidence post-bariatric Surgery Gastric sleeve Non-Obese Gastric band Obese All Bariatric RYGB BP Diversion Time (years) Rousseau, BMJ, 2016
34 Restrictive vs. Malabsorptive Operations NIDDK
35 Approach to Treatment of Osteoporosis Pharmacotherapy (Antiresorptives and anabolics Address Secondary Factors (Drugs and Diseases) Lifestyle Changes (Nutrition, Physical Activity and Fall Prevention) Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services; 2004.
36 Fall Prevention 12 Modifiable Items
37 Therapeutic options Nonpharmacologic therapy / risk reduction Lifestyle Fall prevention Calcium & Vitamin D Pharmacologic therapy Bisphosphonates Teriparatide Testosterone Denosumab (Calcitonin removed from market due to cancer risk) (Strontium CV risk) Khan CMAJ 2007; Ebeling NEJM 2008; Qaseem Ann Intern Med 2008
38 Pharmacologic Therapy: Bisphosphonates Bisphosphonates first line treatment option Alendronate 10 mg/day or 70 mg/wk 7.1% increase in lumbar spine vs. 1.8% with placebo Reduce radiologic fractures at 2 years (0.8% vs. 7.1% with placebo) Risedronate 5 mg/day or 35 mg/wk, or 150 mg/month Reduced risk of hip fractures (RR = 0.25) Zoledronic acid 5 mg IV once yearly Reduced rate of clinical fracture and death in men with hip fracture Khan CMAJ 2007; Ebeling NEJM 2008
39 ONJ Comparative Risks (1) Women age (from Swedish National Bureau of Statistics and database of Olmsted County, MN, USA.) M. Lewiecki 2007 Kanis JA et al. Osteoporos Int. 2001;12: Pharmcoepidemiol Drug Saf. 2003;12: National Center for Health Statistics. JADA. 2006;137:
40 Rough long term harm benefit considerations (ASBMR Task Force) Vertebral fracture benefit Hip fracture benefit Adler, JBMR 2016
41 Other potential complications of bisphosphonate therapy 1) Esophageal Cancer? 2) Atrial Fibrillation? 3) Atypical femoral fractures (Subtrochanteric and mid femoral shaft)
42 Pharmacologic Therapy: Teriparatide 20 mcg/day sc x 24 months (maximum duration) Increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture Reduced risk of moderate/severe vertebral fractures, no nonvertebral fracture data in men Contraindicated if prior radiotherapy Testosterone Hypogonadal men only 8.9% increase in spine vs. placebo No data re: fracture rates Khan CMAJ 2007; Ebeling NEJM 2008; Qaseem Ann Intern Med 2008, Girotra M, Rubin MR, Bilezikian JP 2006 Rev Endocr Metab Disord
43 Percent change in lumbar spine BMD Antiresorptive Therapy Prevents Bone Loss when PTH Discontinued 2D Graph 2 Percent change in BMD Antiresorptive starting before 6 mos (n = 65) Antiresorptive starting after 6 mos (n = 34) No OP use (n=144) 0 EP Visit 1 Visit 2 Visit 3 (6 mos) (18 mos) (30 mos) Lindsay R et al. Arch Intern Med. 2004;164:
44 TRT effect on % change in BMD as a function of pre-treatment serum tt levels TRT effect (% change BMD) 10 5 * * * DB-PC,108 men, > 65 Y, 36 months tt 12.7± 2.7 nmol/l ft 0.2 ± 0.06 nmol/l * : p<0.01 effect of TRT on BMD change related to pretreatment serum tt Pre-treatment serum tt (Nmol/l) Snyder PJ, J Clin Endocrinol Metab 1999;84:
45 Pharmacologic Therapy: Denosumab - most data is in men with metastatic prostate cancer - fracture data in men with osteoporosis extrapolated from female studies - warning re: rebound osteoporosis if discontinued without consolidation with bisphosphonate denosumab sandwich? M. R. Smith et al 2009 NEJM, 361, 8: Toth E et al 2005 Bone 36:47 5
46 Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer Mean Percent Changes from Baseline Bone Mineral Density (BMD) Values Smith MR et al. N Engl J Med 2009;361:
47 Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer Cumulative Incidence of New Vertebral Fracture at 12, 24, and 36 Months Smith MR et al. N Engl J Med 2009;361:
48 Long term effects on Bone Mineral Density Different studies superimposed Reid, I. R. (2015) Short-term and long-term effects of osteoporosis therapies Nat. Rev. Endocrinol. doi: /nrendo
49 Percentage Change From Baseline New Anabolic Agents Abaloparatide Analog of PTHrP Romosozumab (not FDA approved) Humanized anti-sclerostin antibody Both increase lumbar spine and total hip BMD at 12 months more than teriparatide in head-to-head studies Placebo ALN TPTD Romosozumab 210 mg QM Lumbar Spine *P < vs placebo P < vs ALN ʌ P vs TPTD * ʌ * ʌ * ʌ 11.3% Month *P < vs placebo P < vs ALN ʌ P < vs TPTD * Total Hip * ʌ * ʌ 4.1% Month Miller PD et al. JAMA 2016;316: McClung et al. New Engl J Med 2014;370:412-20
50 Available Agents for the treatment of Osteoporosis in Men: Drug Potential advantages Potential disadvantages Oral bisphosphonates Intravenous bisphosphonates Denosumab Teriparatide Strontium ranelate Inexpensive Long experience Long intervals between infusions Potential improved adherence Convenient 6 month dosing Appears to increase BMD up to 6 years, ADT efficacy Anabolic No ONJ or AFF Improves BMD in men May have some anabolic effect Adherence and compliance Side effects: GERD, ONJ, AFF More expensive Side effects: ONJ, AFF More expensive Side effects: ONJ, AFF Expensive Daily subcutaneous injection Less long-term experience New concern about cardiovascular safety Abbreviations: ADT; Androgen Deprivation Therapy; AFF, atypical femoral fracture; BMD, bone mineral density; ONJ, osteonecrosis of the jaw. Bone Research (2014) 2, 14001
CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationScreening Guidelines: Women
The Situation 1 in 2 postmenopausal women and 1 in 5 older men will have an osteoporosis-related fracture in their lifetimes Osteoporosis Definition NIH Consensus Conference A skeletal disorder characterized
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationWho cares about fractures! is more important. October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor Grey Nuns Hospital
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationOsteoporosis Medications: A Case-Based Discussion. Laila S. Tabatabai, MD August 5, 2017
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationBone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh
Bone Health Update 2018 Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh The Problem 50% women and 20% of men have an osteoporotic fracture after age 50 2 million fractures annually
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationReducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.
Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly
More informationUpdate in Osteoporosis: Disclosures. Topics
Update in Osteoporosis: 21 Michael Maricic, M.D. Catalina Pointe Rheumatogy Clinical Associate Professor of Medicine University of Arizona Disclosures Speakers Bureau, Consultant or Clinical Research Grant
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationOptimizing Osteoporosis Management Dr. Philip A. Baer Seacourses Asia CME December 2017
Optimizing Osteoporosis Management Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationAACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationRecent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More information